Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

OTC Monograph User Fees: FDA-Industry Talks Move From Basics To Details

Executive Summary

CDER officials and industry met in July to discuss "the ground rules governing the OTC monograph user fee." CHPA CEO Scott Melville cautions: "No one is going to rush into an agreement that we're going to have to live with for decades."

Advertisement

Related Content

OTC Hangover Remedy Safety On Tap For FDA Advisory Committees
FDA Adds OTC Monograph Staff By Shifting CDER Appropriations
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
User Fees For FY 2017 Make Sponsors Happy, Manufacturers Sad
CDER Asked To Shed More Light On Potential Monograph User Fees
FDA Proposes Illuminating OTC Monograph Process With Sunscreen TEA Framework
OTC Monograph 'Disruption' Could Ride On PDUFA Reauthorization's Back
PCPC: Cosmetic Legislation A Long Shot In 2016, But Objectives Are Clear
“No End In Sight” For Completing OTC Monographs – CDER Director Woodcock

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel